An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nektar Therapeutics
- 08 Aug 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
- 08 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2017.
- 08 Aug 2017 Status changed from recruiting to active, no longer recruiting.